serum calcium levels, and the occurrence of adverse effects. Effective communication and coordination with shared decision-making among healthcare professionals enable timely modifications in dosage, treatment duration, or adjunctive therapies when necessary. This approach optimizes the medication's potential therapeutic effectiveness while minimizing adverse events. ## Review Questions - [Access free multiple choice questions on this topic.](https://www.statpearls.com/account/trialuserreg/?articleid=18770&utm_source=pubmed&utm_campaign=reviews&utm_content=18770) - [Comment on this article.](https://www.statpearls.com/articlelibrary/commentarticle/18770/?utm_source=pubmed&utm_campaign=comments&utm_content=18770) ## References 1. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R., National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-81. \[[PMC free article: PMC4176573](/pmc/articles/PMC4176573/)\] \[[PubMed: 25182228](https://pubmed.ncbi.nlm.nih.gov/25182228)\] 2. Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000 Sep;109(4):267-76. \[[PubMed: 10996576](https://pubmed.ncbi.nlm.nih.gov/10996576)\] 3. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS., Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012 Aug;27(8):1821-9. \[[PubMed: 22437792](https://pubmed.ncbi.nlm.nih.gov/22437792)\] 4. Downs RW, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, Wang L, Smith ME, Gormley GJ, Melton ME. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000 May;85(5):1783-8. \[[PubMed: 10843152](https://pubmed.ncbi.nlm.nih.gov/10843152)\] 5. Mu√±oz-Torres M, Alonso G, Raya MP. Calcitonin therapy in osteoporosis. Treat Endocrinol. 2004;3(2):117-32. \[[PubMed: 15743107](https://pubmed.ncbi.nlm.nih.gov/15743107)\] 6. Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int. 2012 Jan;23(1):17-38. \[[PubMed: 21660557](https://pubmed.ncbi.nlm.nih.gov/21660557)\] 7. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. Endocr Pract. 2016 Sep;22(9):1111-8. \[[PubMed: 27643923](https://pubmed.ncbi.nlm.nih.gov/27643923)\] 8. Singer FR. Clinical efficacy of salmon calcitonin in Paget's disease of bone. Calcif Tissue Int. 1991;49 Suppl 2:S7-8. \[[PubMed: 1933617](https://pubmed.ncbi.nlm.nih.gov/1933617)\] 9. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism